LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study von Mazieres, J., Kim, T.M., Lim, B.K., Wislez, M., Dooms, C., Finocchiaro, G., Hayashi, H., Liam, C.K., Raskin, J., Tho, L.M., de Marinis, F., Nadal, E., Smit, E., Le, X., Brutlach, S., O'Brate Grupp, A.M., Adrian, S., Ellers-Lenz, B., Karachaliou, N., Wu, Y-L.

Volltext

1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib von Rolfo, C.D., OBrate Grupp, A.M., Menzel, C., Bruns, R., Juraeva, D., Stroh, C., Johne, A., Paik, P.K.

Volltext

1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION von Christopoulos, P., Ekman, S., Guisier, F., Ho, C., Blasi, M., Brunnstrom, H., Cvetkovic, J., Kazdal, D., Kuon, J.B., Haglund de Flon, F., Stenzinger, A., Wong, S., Hatswell, A., McLean, T., Bergman, S., Orlowski, K., OBrate Grupp, A.M., Vioix, H., Thomas, M.

Volltext

Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study von Mazieres, J, Kim, T.M, Lim, B.K, Wislez, M, Dooms, C, Finocchiaro, G, Hayashi, H, Liam, C.K, Raskin, J, Tho, L.M, de Marinis, F, Nadal, E, Smit, E, Le, X, Brutlach, S, Grupp, A.M. O'Brate, Adrian, S, Ellers-Lenz, B, Karachaliou, N, Wu, Y.L

Volltext